- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06357845
Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
Healthy Futures Research Study: Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is:
- What biological impact will be measured based on DNA damage?
- In participants who provide a biospecimen, how are biomarker changes related to proximity to the derailment and variations in residents' health histories and behaviors?
Participants will:
- Complete a brief survey asking about experiences related to the February 3, 2023 train derailment, health experiences, and concerns following the derailment, and background information regarding health history.
- Possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings.
- Receive communication about study updates and future research opportunities.
- A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded.
Study Overview
Status
Conditions
Detailed Description
On February 3, 2023, at 8:55 pm EST, over 30 train cars from a Norfolk Southern train carrying hazardous chemicals derailed in the village of East Palestine, Ohio. In a few hours, residents within a 1- mile radius were ordered to evacuate, followed by several shelter-in-place orders. By February 6, the evacuation zone was expanded, and a controlled burn was implemented in the hopes of preventing an explosion. A week later, the Environmental Protection Agency (EPA) announced vinyl chloride, butyl acrylate, ethylhexyl acrylate, and ethylene glycol monobutyl ether were released into the air, surface soil, and surface waters. Although the EPA failed to detect contaminants at concerning levels for human health in the East Palestine region on February 12, East Palestine residents with private wells were recommended to use bottled water only four days later, and subsequent testing has detected elevated chemical levels in the region. The EPA instructed Norfolk Southern to expand testing and include dioxin testing on March 2. Four days later seven members of a 15-person CDC/ATSDR team reported sore throats, headaches, coughing and nausea after conducting Assessment of Chemical Exposure (ACE) surveys. The inconsistent messaging from the EPA and other governmental agencies have frustrated East Palestine and surrounding community (EPSC) residents, and generated concerns regarding long-term health effects.
This study has several aims:
- Establish the Healthy Futures Pilot Cohort utilizing a community-engaged research approach
- Compare genotoxicity levels arising from chemical exposure by geographical proximity and direction from the train derailment epicenter utilizing the somatic mutation rate in DNA among residents
- Understand experiences during and post-disaster with respect to effects on quality of life, perceived stressors, future prospects, and overall health-and how acute disasters shape risk perception, coping strategies, and access to health-protective resources through semi-structured interviews.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fredrick R Schumacher, PhD
- Phone Number: 216-368-0351
- Email: healthyfutures@case.edu
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Case Western Reserve University, Case Comprehensive Cancer Center
-
Contact:
- Fredrick Schumacher, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Residence on February 3rd, 2023 in Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, PA, or Lawrence County, PA.
- Current residence in the United States.
Exclusion Criteria:
- Address provided for February 3rd, 2023 not in Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, PA, or Lawrence County, PA
- Invalid address provided for February 3rd, 2023 residence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Residents effected by the Derailment event
Eligible residents must be adult participants from Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, Pennsylvania, or Lawrence County, Pennsylvania.
|
Participants will complete a brief web-based survey asking about their experiences related to the February 3, 2023 train derailment, health experiences and concerns following the derailment, and background information regarding their health history.
The survey will last approximately 15 minutes.
Participants may possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings.
Participants will be asked which samples they are interested in providing.
Participants will receive a specific sample collection kit based on their selection.
For blood samples, participants will receive a mailed collection kit at their mailing address.
A member of the research team will reach out to schedule blood sample collection, which may take place at home with a trained phlebotomist or at a designated collection site.
A total of 1-2 teaspoons of blood (5-10 milliliters) will be collected at a one-time blood draw.
For either saliva, hair, and/or toenail clippings, participants will be sent a sample collection kit and receive instructions at their mailing address.
This kit also includes a return mailing envelope.
Participants will provide the selected samples in the collection kits, place them in the return mailing envelope, and send them back to the research team.
By consenting to participate in this study, the research team will send updates about the research results and any additional study opportunities to participants.
A total of 40 study participants will be recruited to participate in a 90-minute interview with open-ended questions.
The interviews will be video and audio-recorded.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geographic Association of Somatic Mutation Rates
Time Frame: Up to 24 months
|
The primary outcome measure is somatic mutation rates in association with geographical distance from the train derailment epicenter.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported Symptomology Association of Somatic Mutation Rates
Time Frame: Up to 24 months
|
The secondary outcome measure is somatic mutation rates in association with self-reported symptomology at time of exposure.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fredrick R Schumacher, PhD, Case Western Reserve University, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE5Z24
- 1R21ES036031-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Somatic Mutation
-
The Wellcome Sanger InstituteCambridge University Hospitals NHS Foundation Trust; Hull University Teaching...Enrolling by invitation
-
The Wellcome Sanger InstituteEnrolling by invitationCancer | Somatic MutationUnited Kingdom
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
-
University of California, San FranciscoNot yet recruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult | Hereditary Cancer | Somatic MutationUnited States
-
The Wellcome Sanger InstituteEnrolling by invitation
-
Daniel MarotiNot yet recruitingSomatic Symptom Disorder | Somatic Symptom and Related Disorders | Functional Somatic Disorder | Functional Somatic SyndromeSweden
-
A.T. Still University of Health SciencesCompletedSomatic Dysfunction of Cranial Region | Somatic Dysfunction of Cervical Spine | Somatic Dysfunction of Lumbar Spine | Somatic Dysfunction of SacrumUnited States
-
Daniel MarotiWayne State UniversityRecruitingSomatic Symptom Disorder | Functional Somatic Disorder | Functional Somatic SyndromesSweden
-
Daniel MarotiNot yet recruitingPersistent Physical Symptoms (PPS) | Somatic Symptom Disorder (DSM-5) | Functional Somatic Disorder | Functional Somatic Syndromes
-
Xueding WangSun Yat-sen UniversityUnknownGastrointestinal Stromal Tumors | Somatic Mutation | Plasma Concentration | Germline MutationChina
Clinical Trials on Survey
-
Johns Hopkins Bloomberg School of Public HealthPontificia Universidad JaverianaCompletedNoncommunicable Diseases | Surveys and QuestionnairesColombia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Université de Cergy PontoiseCompleted
-
Sarasota Memorial Health Care SystemEnrolling by invitation
-
Ohio State UniversityWithdrawnMedicare Part DUnited States
-
Johns Hopkins Bloomberg School of Public HealthIfakara Health InstituteCompletedNoncommunicable Diseases | Surveys and QuestionnairesTanzania
-
Memorial Sloan Kettering Cancer CenterCompletedInpatients With Limited English ProficiencyUnited States
-
Lawson Health Research InstituteCompletedEvaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation ParticipationMyocardial Infarction | Unstable Angina | Coronary Angioplasty | Coronary Artery Bypass SurgeryCanada
-
University GhentCompletedStroke | Upper Extremity Paresis | Survey